Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (355)	4/9/2003 6:22:21 PM
From: tuck	Read Replies (1) \| Respond to of 887

That wouldn't surprise me; interim data from the first patients enrolled. Yeah, it doesn't count for much, interim PI data. Neither does this: >>PALO ALTO, Calif., April 9 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK - News) announced the identification of novel small molecule drug candidates for important cancer targets through the application of the company's proprietary drug discovery technology, TRAP. Several of these candidates resulted from collaborations between Telik and leading cancer research centers. The studies were published in the March 2003 Proceedings of the Annual Meeting of the American Association for Cancer Research. High efficiency screening: discovery of new cancer drug leads with Telik's TRAP technology (Abstract # 4576). -- PARG inhibitors: When DNA is damaged through the effects of cancer chemotherapy or radiation therapy, PARG is upregulated in order to protect the cell. Inhibition of PARG may provide benefit in sensitizing cancer cells to treatment. Small molecule inhibitors of PARG have been discovered through TRAP in a collaboration with scientists at the University of Arizona Cancer Center (AZCC). -- Inhibitors of beta-1 integrin-mediated cell adhesion. Tumor cell adhesion to the extracellular matrix is an important step in the spread of cancer. The beta-1 integrins are receptor proteins involved in adhesion and expressed in primary and metastatic cancers. Inhibition of beta-1 integrin activity may disrupt adhesion and interfere with metastasis. Small molecule inhibitors of beta-1 integrins have been identified through TRAP in a collaboration with scientists at AZCC. -- Inhibitors of human intestinal carboxylesterase (hiCE). The chemotherapeutic drug irinotecan causes severe diarrhea due to hiCE activation. A specific inhibitor of hiCE, used in combination with irinotecan, might reduce this toxicity. TRAP has enabled the identification of small molecule hiCE inhibitors which are currently being assessed for in vivo activity in collaboration with scientists at St. Jude Children's Research Hospital. Biochemical and cellular characterizations of c-Raf kinase inhibitors discovered through TRAP technology (Abstract # LB-124). -- Raf kinase inhibitors. Mutations of the ras oncogene are found in many tumor types and can lead to abnormal cell proliferation through a pathway which includes Raf kinase. Small molecule inhibitors of Raf kinase identified through TRAP have shown anti-proliferative activity specific for cancer cells.<< snip Cheers, Tuck